Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.

Autor: Finn MB; Moderna, Inc., 325 Binney St., Cambridge, MA 02142, USA., Penfound TA; Department of Medicine, University of Tennessee Health Science Center, 956 Court Ave., Memphis, TN 38163, USA., Salehi S; Department of Medicine, University of Tennessee Health Science Center, 956 Court Ave., Memphis, TN 38163, USA., Ogega CO; Moderna, Inc., 325 Binney St., Cambridge, MA 02142, USA., Dold C; Moderna, Inc., 325 Binney St., Cambridge, MA 02142, USA., Plante O; Moderna, Inc., 325 Binney St., Cambridge, MA 02142, USA. Electronic address: Obadiah.Plante@modernatx.com., Dale JB; Department of Medicine, University of Tennessee Health Science Center, 956 Court Ave., Memphis, TN 38163, USA. Electronic address: jbdale@uthsc.edu.

Publikováno v: Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 126205. Date of Electronic Publication: 2024 Aug 13.

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.

Autor: Freyn AW; Moderna Inc., Cambridge, 02139 MA, USA., Atyeo C; Moderna Inc., Cambridge, 02139 MA, USA., Earl PL; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Americo JL; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Chuang GY; Moderna Inc., Cambridge, 02139 MA, USA., Natarajan H; Moderna Inc., Cambridge, 02139 MA, USA., Frey TR; Moderna Inc., Cambridge, 02139 MA, USA., Gall JG; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Moliva JI; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Hunegnaw R; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Asthagiri Arunkumar G; Moderna Inc., Cambridge, 02139 MA, USA., Ogega CO; Moderna Inc., Cambridge, 02139 MA, USA., Nasir A; Moderna Inc., Cambridge, 02139 MA, USA., Santos G; Moderna Inc., Cambridge, 02139 MA, USA., Levin RH; Moderna Inc., Cambridge, 02139 MA, USA., Meni A; Moderna Inc., Cambridge, 02139 MA, USA., Jorquera PA; Moderna Inc., Cambridge, 02139 MA, USA., Bennett H; Moderna Inc., Cambridge, 02139 MA, USA., Johnson JA; Moderna Inc., Cambridge, 02139 MA, USA., Durney MA; Moderna Inc., Cambridge, 02139 MA, USA., Stewart-Jones G; Moderna Inc., Cambridge, 02139 MA, USA., Hooper JW; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, 21702 MD, USA., Colpitts TM; Moderna Inc., Cambridge, 02139 MA, USA., Alter G; Moderna Inc., Cambridge, 02139 MA, USA., Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA., Carfi A; Moderna Inc., Cambridge, 02139 MA, USA., Moss B; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 MD, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2023 Oct 04; Vol. 15 (716), pp. eadg3540. Date of Electronic Publication: 2023 Oct 04.

Convergent antibody responses are associated with broad neutralization of hepatitis C virus.

Autor: Skinner NE; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.; Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States., Ogega CO; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Frumento N; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Clark KE; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Yegnasubramanian S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schuebel K; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Meyers J; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Gupta A; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Wheelan S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Cox AL; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Crowe JE Jr; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, United States., Ray SC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bailey JR; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Mar 24; Vol. 14, pp. 1135841. Date of Electronic Publication: 2023 Mar 24 (Print Publication: 2023).

Durable SARS-CoV-2 B cell immunity after mild or severe disease.

Autor: Ogega CO; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Skinner NE; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Blair PW; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Park HS; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Littlefield K; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Ganesan A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Dhakal S; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Ladiwala P; Advanced Mammalian Biomanufacturing Innovation Center, Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Antar AA; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ray SC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Betenbaugh MJ; Advanced Mammalian Biomanufacturing Innovation Center, Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Pekosz A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Klein SL; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Manabe YC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cox AL; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Bailey JR; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2021 Apr 01; Vol. 131 (7).

Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Autor: Colbert MD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Flyak AI; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ogega CO; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Kinchen VJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Massaccesi G; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hernandez M; Integral Molecular, Inc., Philadelphia, Pennsylvania, USA., Davidson E; Integral Molecular, Inc., Philadelphia, Pennsylvania, USA., Doranz BJ; Integral Molecular, Inc., Philadelphia, Pennsylvania, USA., Cox AL; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Crowe JE Jr; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Bailey JR; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA jbailey7@jhmi.edu.

Publikováno v: Journal of virology [J Virol] 2019 Jun 28; Vol. 93 (14). Date of Electronic Publication: 2019 Jun 28 (Print Publication: 2019).